title: Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
abstract: The major problem in the treatment of acute myeloid leukemia (AML) patients results from multidrug resistance to administered anticancer agents. Drug resistance proteins, MDR1 and MRP1, which work as drug efflux pumps, can mediate the multidrug resistance of human leukemia cells. In this study, the mechanisms of resistance to doxorubicin-induced cell death in human HL60 AML cells were examined. Continuous exposure of cells to step-wise increasing concentrations of doxorubicin resulted in the selection of HL60/DOX cells, which expressed about 10.7-fold resistance as compared to parental sensitive cells. The expression analyses of MRP1 and MDR1 drug efflux proteins in doxorubicin-sensitive and -resistant HL60 cells revealed that there was an upregulation of MRP1 gene in HL60/DOX cells as compared to parental sensitive cells. On the other hand, while there was no expression of MDR1 gene in parental cells, the expression of MDR1 gene was upregulated in HL60/DOX cells. HL60/DOX cells also showed cross-resistance to cytosine arabinoside (Ara-c). This resistance was reversed by a combination therapy of Ara-c and cyclosporine A. However, the expression levels of CD15 and CD16 surface markers were significantly decreased in HL60/DOX cells.
authors.affiliation: Middle East Technical University, Department of Biological Sciences, 06531 Ankara, Turkey. yusufbaran@iyte.edu.tr
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Baran
authors.forename: Bala
authors.initials: B
authors.lastname: Gür
authors.forename: Pelin
authors.initials: P
authors.lastname: Kaya
authors.forename: Ali Uğur
authors.initials: AU
authors.lastname: Ural
authors.forename: Ferit
authors.initials: F
authors.lastname: Avcu
authors.forename: Ufuk
authors.initials: U
authors.lastname: Gündüz
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D016572:Cyclosporine / Q000493:pharmacokinetics; D003561:Cytarabine / Q000493:pharmacokinetics; D004317:Doxorubicin / Q000493:pharmacokinetics*; D018432:Drug Resistance, Multiple / Q000187:drug effects / Q000235:genetics*; D004359:Drug Therapy, Combination; D018922:HL-60 Cells; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D016256:Lewis X Antigen; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D017452:Receptors, IgG; D015854:Up-Regulation / Q000235:genetics
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D016572:Cyclosporine; D003561:Cytarabine; D004317:Doxorubicin; D016256:Lewis X Antigen; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D017452:Receptors, IgG; C421109:multidrug resistance-associated protein 1